arrow
L

Lee M. Kaplan

geisel school of medicine at dartmouth
H指数:73
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

作者更正:索沃杜肽在肥胖和代谢功能障碍相关脂肪性肝病成人患者中的应用:SYNCHRONIZE-MASLD,一项随机、双盲、安慰剂对照的3期临床试验

2026-08-250
OAAI
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

肥胖和代谢功能障碍相关的脂肪变性肝病成人的Survodutide: synchrone-masld,一项随机,双盲,安慰剂对照的3期试验

2026-06-070
OAAI
International Expert Consensus on Definitions and Management of Weight Recurrence and Suboptimal Response After Metabolic and Bariatric Surgery: A Delphi Study

《代谢与减肥手术后体重复发及疗效不佳的定义与管理:国际专家共识(一项德尔菲研究)》

2026-03-170
PRE
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes

SYNCHRONIZE™-2随机III期临床试验中,survodutide(一种胰高血糖素受体/GLP-1受体双重激动剂)用于2型糖尿病人群肥胖治疗的基线特征。

2025-11-110
OAAI
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)

Survodutide治疗肥胖:一项随机、双盲、安慰剂对照的III期试验(SYNCHRONIZE™-1)中参与者的基线特征

2025-11-040
OAAI
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

Retatrutide用于治疗肥胖、阻塞性睡眠呼吸暂停和膝关节骨关节炎:TRIUMPH注册临床试验的原理与设计

2025-10-150
OAAI
Missing the Target: A Scoping Review of the Use of Percent Weight Loss for Obesity Management

目标缺失:关于体重百分比损失在肥胖管理中应用的概述性综述

2025-06-030
OAAI